SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Novo Nordisk A/S NONOF OTC

Other OTC • Healthcare • Biotechnology • DK • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Novo Nordisk A/S (NONOF) is a Biotechnology company in the Healthcare sector, currently trading at $38.82. It has a SharesGrow Score of 87/100, indicating a strong investment profile with 6 out of 7 criteria passed.

Financials: revenue is $308.4B, +20.8%/yr average growth. Net income is $102.2B, growing at +24.2%/yr. Net profit margin is 33.1% (strong). Gross margin is 80.3% (-3.6 pp trend).

Balance sheet: total debt is $137.9B against $193.6B equity (Debt-to-Equity (D/E) ratio 0.71, moderate). Current ratio is 0.8 (tight liquidity). Debt-to-assets is 25.5%. Total assets: $541.7B.

Analyst outlook: 18 / 25 analysts rate NONOF as buy (72%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 100/100 (Pass), Health 50/100 (Partial), Moat 85/100 (Pass), Future 75/100 (Pass), Income 100/100 (Pass).

NONOF SharesGrow Score Overview

87/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 85/100

Gross margin is + market cap

FUTURE 75/100

Analyst outlook — as buy

INCOME 100/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NONOF

NONOF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

NONOF: +20.8%/yr revenue is, +24.2%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

NONOF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet NONOF: Debt-to-Equity (D/E) ratio 0.71 (moderate), Current ratio is 0.8 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

NONOF: Gross margin is 80.3% (-3.6 pp trend), $172B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 85/100. ≥ 70 = Pass.

View details →

Analyst outlook: 18 / 25 analysts rate NONOF as buy (72%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

NONOF: Net profit margin is 33.1%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range34-82.5

Volume157.01K

Avg Volume (30D)295.1K

Market Cap$172.47B

Beta (1Y)0.27

Dividend Yield$1.4776

Share Statistics

EPS (TTM)23.00

Shares Outstanding$4.44B

IPO Date2010-05-07

Employees77,406

CEOMaziar Mike Doustdar

Financial Highlights & Ratios

Revenue (TTM)$308.36B

Gross Profit$247.74B

EBITDA$149.1B

Net Income$102.2B

Operating Income$134.71B

Total Cash$26.9B

Total Debt$137.88B

Net Debt$111.48B

Total Assets$541.67B

Price / Earnings (P/E)1.7

Price / Sales (P/S)0.56

Analyst Forecast

Rating ConsensusBuy

Analysts Covering25

Buy 72% Hold 16% Sell 12%

Company Info

CountryDK

ExchangeOther OTC

CurrencyUSD

ISINDK0062498333

Price Chart

NONOF

Novo Nordisk A/S ↗ · Other OTC

Healthcare • Biotechnology

34.00 52WK RANGE 82.50

People Also View

DICE Therapeutics, Inc.

Viridian Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message